Item 5.03 Amendments to Articles of Incorporation or By-laws; Change in Fiscal


           Year

On December 9, 2022, Abbott's Board of Directors amended and restated Abbott's by-laws (the "Amended and Restated By-Laws"), effective immediately. The Amended and Restated By-laws, among other things:

· Update and clarify the procedural mechanics and information requirements for


   shareholder nominations of directors and shareholder proposals (other than
   proposals to be included in Abbott's proxy materials pursuant to Rule 14a-8
   under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) at
   shareholder meetings, including to address matters relating to Rule 14a-19
   under the Exchange Act;

· Update certain procedural mechanics for special meetings of shareholders;

· Clarify the powers of the Board and the Chair of a shareholder meeting to


   regulate conduct at such meeting; and

· Make various other updates, including ministerial and conforming changes, as


   well as changes in furtherance of gender neutrality.

The foregoing summary of the amendments does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended and Restated By-laws, which are attached hereto as Exhibit 3.1 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits






Exhibit No.  Description
  3.1          Amended and Restated By-laws of Abbott Laboratories, effective as of
             December 9, 2022

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

© Edgar Online, source Glimpses